NCT03290443 - A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

October 26, 2018

Study Completion Date

October 26, 2018

Conditions

Hepatic Impairment

Interventions

DRUG

Enasidenib

100 mg enasidenib (CC-90007)

Trial Locations (5)

Orlando Clinical Research Center OCRC, Orlando

New Orleans Center of Clinical Research, Knoxville

DaVita Clinical Research, Minneapolis

DaVita Clinical Research, Lakewood

Clinical Pharmacology of Miami, LLC, Miami